CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 25 enrolled
Drug / intervention
DUR-928 Topical Solution +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03837743
NCT03837743Phase 2Completed

A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Proof of Concept Comparison Study of the Safety and Efficacy of DUR-928 Topical Solution With Occlusion in Subjects With Mild to Moderate Plaque Psoriasis

Durect·interventional·Posted Feb 12, 2019·Updated Sep 2, 2022

In Brief

A Phase 2 clinical trial evaluating DUR-928 Topical Solution and Vehicle Topical Solution for Plaque Psoriasis. Completed, enrolled 25 participants across 5 sites.

Detailed Summary

This Phase 2 study has been designed to determine and compare the safety, tolerability, and efficacy of DUR-928 topical solution with that of the vehicle topical solution when applied once daily for approximately four weeks in subjects with plaque psoriasis. Subjects will be instructed (randomly assigned) to apply DUR-928 solution to a target lesion on one arm and vehicle solution to a target lesion on the opposite arm once daily for up to four weeks. Subjects will occlude the treated areas for approximately two hours after each application.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsTherapeutics, Inc.

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedFeb 12, 2019
Enrollment StartFeb 21, 2019
Primary CompletionNov 11, 2019
Study CompletionMay 20, 2020
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 7.4 years ago

Interventions

DUR-928 Topical Solutiondrug

Topical solution containing active drug

Vehicle Topical Solutiondrug

Topical solution containing no active drug